Delayed blood count recovery is a major cause of morbidity and mortality in people undergoing stem cell transplantation or intensive chemotherapy. Treatment with hematopoietic growth factors can accelerate hematopoiesis, but prolonged cytopenias still occur. A new study shows that inhibition of dipeptidylpeptidase IV augments the activity of certain hematopoietic growth factors, providing a new approach to potentially treat cytopenias (pages 1786–1796).
This is a preview of subscription content, log in via an institution to check access.
Debbie Maizels
References
Mauch, P. et al. Int. J. Radiat. Oncol. Biol. Phys. 31, 1319–1339 (1995).
Kuderer, N.M. et al. J. Clin. Oncol. 25, 3158–3167 (2007).
Broxmeyer, H.E. et al. Nat. Med. 18, 1786–1796 (2012).
Lieschke, G.J. et al. Blood 84, 1737–1746 (1994).
Wu, H. et al. Cell 83, 59–67 (1995).
de Sauvage, F.J. et al. J. Exp. Med. 183, 651–656 (1996).
Lambeir, A.M. et al. J. Biol. Chem. 10, 29839–29845 (2001).
Christopherson, K.W. II et al. Science 305, 1000–1003 (2004).
Bohlius, J. et al. Lancet 373, 1532–1542 (2009).
Ahren, B. Expert Opin. Emerg. Drugs 13, 593–607 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hsu, YM., Link, D. Enhancing hematopoietic growth factor performance. Nat Med 18, 1740–1741 (2012). https://doi.org/10.1038/nm.3022
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3022
- Springer Nature America, Inc.